Drugs / Phenformin

Trials 2 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03026517 Jan 2017 → Jan 2025 melanoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05003492 Sep → Oct 2021 COVID-19 Amr kamel khalil Ahmed Unknown No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Phenformin “Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose.” NCT05003492
1

NCT03026517

Known as Debei ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as Dibotin s.r. ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as Fenformina ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as NSC-23100 ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as PHENFORMIN ACETIC ACID SALT ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as Phenformin hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as PHENFORMIN HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Known as Phenformine ChEMBL registry synonym — accepted as the source's own label CHEMBL170988
Action Inhibit “Phenformin is expected to potentially attach to ACE2 receptors and lead to its downregulation, an inhibitory mechanism which may combat and block COVID-19 infection in lung...” NCT05003492
Modality Small molecule CHEMBL170988
Route Inhaled “The phenformin will be utilized as aerosolized by inhalation for COVID-19 treatment” NCT05003492
Target ACE2 “Phenformin is expected to potentially attach to ACE2 receptors and lead to its downregulation” NCT05003492